{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:07:09Z","timestamp":1780790829082,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00280-016-3033-7","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T12:52:24Z","timestamp":1461243144000},"page":"1193-1200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma"],"prefix":"10.1007","volume":"77","author":[{"given":"Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Kevin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Rink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Wasif","family":"Saif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,21]]},"reference":[{"issue":"1","key":"3033_CR1","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9(1):327\u2013337","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3033_CR2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115\u2013124","journal-title":"N Engl J Med"},{"issue":"22","key":"3033_CR3","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584\u20133590","journal-title":"J Clin Oncol"},{"issue":"9544","key":"3033_CR4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329\u20131338","journal-title":"Lancet"},{"issue":"6","key":"3033_CR5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul J-L et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. NEJM 364(6):501\u2013513","journal-title":"NEJM"},{"key":"3033_CR6","first-page":"719","volume":"7","author":"S Kim","year":"2014","unstructured":"Kim S, Ding W, Zhang L et al (2014) Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials. Onco Targets Ther 7:719\u2013728","journal-title":"Onco Targets Ther"},{"issue":"17","key":"3033_CR7","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1016\/j.ejca.2013.06.041","volume":"49","author":"M Reni","year":"2013","unstructured":"Reni M, Cereda S, Milella M et al (2013) Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomized trial. Eur J Cancer 49(17):3609\u20133615","journal-title":"Eur J Cancer"},{"issue":"15","key":"3033_CR8","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2014.57.3105","volume":"33","author":"N Ready","year":"2015","unstructured":"Ready N, Pang HH, Gu L et al (2015) Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study\u2014CALGB 30504 (alliance). J Clin Oncol 33(15):1660\u20131665","journal-title":"J Clin Oncol"},{"issue":"2","key":"3033_CR9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1634\/theoncologist.2009-0303","volume":"15","author":"A Ravaud","year":"2010","unstructured":"Ravaud A, Fouchardiere C, Asselineau J et al (2010) Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 15(2):212\u2013213","journal-title":"Oncologist"},{"issue":"16","key":"3033_CR10","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun SY, Rosenberg LM, Wang X et al (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65(16):7052\u20137058","journal-title":"Cancer Res"},{"issue":"6980","key":"3033_CR11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","volume":"428","author":"HG Wendel","year":"2004","unstructured":"Wendel HG, De Stanchina E, Fridman JS et al (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428(6980):332\u2013337","journal-title":"Nature"},{"issue":"16","key":"3033_CR12","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1111\/bph.12749","volume":"171","author":"M Moschetta","year":"2014","unstructured":"Moschetta M, Reale A, Marasco C et al (2014) Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations. Br J Pharmacol 171(16):3801\u20133813","journal-title":"Br J Pharmacol"},{"issue":"5","key":"3033_CR13","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","volume":"15","author":"HA Lane","year":"2009","unstructured":"Lane HA, Wood JM, McSheehy PM et al (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 15(5):1612\u20131622","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3033_CR14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.exphem.2011.01.005","volume":"39","author":"A Batista","year":"2011","unstructured":"Batista A, Barata JT, Raderschall E et al (2011) Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 39(4):457\u2013472","journal-title":"Exp Hematol"},{"issue":"2","key":"3033_CR15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clgc.2012.09.008","volume":"11","author":"NJ Vogelzang","year":"2013","unstructured":"Vogelzang NJ, Bhor M, Liu Z et al (2013) Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US oncology network. Clin Genitourin Cancer 11(2):115\u2013120","journal-title":"Clin Genitourin Cancer"},{"issue":"22","key":"3033_CR16","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271\u20132281","journal-title":"N Engl J Med"},{"issue":"18","key":"3033_CR17","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116(18):4256\u20134265","journal-title":"Cancer"},{"key":"3033_CR18","first-page":"9727","volume":"60","author":"KT Flaherty","year":"2015","unstructured":"Flaherty KT, Manoma JB, Pins M et al (2015) BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma\u2014a trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol 60:9727","journal-title":"J Clin Oncol"},{"key":"3033_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1479-5876-3-39","volume":"3","author":"KR Molhoek","year":"2005","unstructured":"Molhoek KR, Brautigan DL, Slingluff CL et al (2005) Synergistic inhibition of human melanoma proliferation by combination treatment with B-raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Transl Med 3:39\u201345","journal-title":"J Transl Med"},{"issue":"3","key":"3033_CR20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","volume":"45","author":"BE Storer","year":"1989","unstructured":"Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45(3):925\u2013937","journal-title":"Biometrics"},{"issue":"2","key":"3033_CR21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/FTD.0b013e31827efd9e","volume":"35","author":"NA Lankheet","year":"2013","unstructured":"Lankheet NA, Steeghs N, Rosing H et al (2013) Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring. Ther Drug Monit 35(2):168\u2013176","journal-title":"Ther Drug Monit"},{"key":"3033_CR22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/j.1552-4604.1997.tb04318.x","volume":"37","author":"JJ Zimmerman","year":"1997","unstructured":"Zimmerman JJ, Kahan BD (1997) Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 37:405\u2013415","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3033_CR23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00280-013-2117-x","volume":"71","author":"DK Pawaskar","year":"2013","unstructured":"Pawaskar DK, Straubinger RM, Fetterly GJ et al (2013) Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol 71(5):1231\u20131240","journal-title":"Cancer Chemother Pharmacol"},{"key":"3033_CR24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12885-015-1363-1","volume":"15","author":"Y Pignochino","year":"2015","unstructured":"Pignochino Y, Dell\u2019Aglio C, Inghilleri S et al (2015) The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer 15:374","journal-title":"BMC Cancer"},{"issue":"8","key":"3033_CR25","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2011-0078","volume":"16","author":"I Altomare","year":"2011","unstructured":"Altomare I, Bendell JC, Bullock KE et al (2011) A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 16(8):1131\u20131137","journal-title":"Oncologist"},{"issue":"13","key":"3033_CR26","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1158\/1078-0432.CCR-12-3919","volume":"19","author":"CL Slingluff","year":"2013","unstructured":"Slingluff CL, Petroni GR, Molhoek KR et al (2013) Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190\/Mel47). Clin Cancer Res 19(13):3611\u20133620","journal-title":"Clin Cancer Res"},{"key":"3033_CR27","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-09-0717","volume":"15","author":"BI Rini","year":"2009","unstructured":"Rini BI, Garcia JA, Cooney MM et al (2009) A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 15:6277\u20136283","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3033_CR28","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1078-0432.CCR-10-2061","volume":"17","author":"TC Gangadhar","year":"2011","unstructured":"Gangadhar TC, Cohen EW, Wu K et al (2011) Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res 17(7):1956\u20131963","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3033-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3033-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:07:41Z","timestamp":1559038061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3033-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,21]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3033"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3033-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,21]]}}}